Breast lymphoma: General review.

Breast disease Pub Date : 2023-01-01 DOI:10.3233/BD-220051

Emad M N Rezkallah, Andrew Elsaify, Su M M Tin, Debdeep Dey, Wael M Elsaify

{"title":"Breast lymphoma: General review.","authors":"Emad M N Rezkallah, Andrew Elsaify, Su M M Tin, Debdeep Dey, Wael M Elsaify","doi":"10.3233/BD-220051","DOIUrl":null,"url":null,"abstract":"Background: Lymphoma of the breast can be classified as either primary breast lymphoma (PBL) or secondary to systemic lymphoma (SBL). PBL is a rare disease with Diffuse Large B cell Lymphomas (DLBCL) being the most common subtype.Objectives: In the current study, we represented eleven cases diagnosed with breast lymphoma in our trust; two of them had PBL and nine had SBL. We focused mainly on the clinical presentation, diagnosis, management and outcomes.Methods: We did this retrospective review for all breast lymphoma patients who were diagnosed in our trust during the periods from 2011-2022. Patients' data were obtained from the hospital recording system. We followed up these patients thus far to identify the outcome of treatment in each patient.Results: Eleven patients were included in our review. All patients were females. Average age of diagnosis was 66.1 ± 13 years of age. Eight patients were diagnosed with DLBCL, two patients were diagnosed with follicular lymphomas, and the last one had lymphoplasmacytic lymphoma. Chemotherapy +∕- radiotherapy was the standard treatment regimen in all patients. Four patients passed away within one year of chemotherapy, five patients achieved complete remission, one patient had two relapses and is still under treatment, while the last patient was diagnosed recently and still awaiting treatment.Conclusion: Primary breast lymphoma is an aggressive disease. The treatment for PBL is mainly systemic with chemoradiotherapy. The role of surgery is now limited to the diagnosis of the disease. Early diagnosis and proper treatment are crucial for the management of such cases.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"197-205"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-220051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lymphoma of the breast can be classified as either primary breast lymphoma (PBL) or secondary to systemic lymphoma (SBL). PBL is a rare disease with Diffuse Large B cell Lymphomas (DLBCL) being the most common subtype.

Objectives: In the current study, we represented eleven cases diagnosed with breast lymphoma in our trust; two of them had PBL and nine had SBL. We focused mainly on the clinical presentation, diagnosis, management and outcomes.

Methods: We did this retrospective review for all breast lymphoma patients who were diagnosed in our trust during the periods from 2011-2022. Patients' data were obtained from the hospital recording system. We followed up these patients thus far to identify the outcome of treatment in each patient.

Results: Eleven patients were included in our review. All patients were females. Average age of diagnosis was 66.1 ± 13 years of age. Eight patients were diagnosed with DLBCL, two patients were diagnosed with follicular lymphomas, and the last one had lymphoplasmacytic lymphoma. Chemotherapy +∕- radiotherapy was the standard treatment regimen in all patients. Four patients passed away within one year of chemotherapy, five patients achieved complete remission, one patient had two relapses and is still under treatment, while the last patient was diagnosed recently and still awaiting treatment.

Conclusion: Primary breast lymphoma is an aggressive disease. The treatment for PBL is mainly systemic with chemoradiotherapy. The role of surgery is now limited to the diagnosis of the disease. Early diagnosis and proper treatment are crucial for the management of such cases.

查看原文本刊更多论文

乳腺淋巴瘤：综述。

背景：乳腺淋巴瘤可分为原发性乳腺淋巴瘤（PBL）和继发性全身淋巴瘤（SBL）。原发性乳腺淋巴瘤是一种罕见疾病，弥漫大 B 细胞淋巴瘤（DLBCL）是最常见的亚型：在本研究中，有 11 例乳腺淋巴瘤患者在我院确诊，其中 2 例为 PBL，9 例为 SBL。我们主要关注临床表现、诊断、处理和结果：我们对 2011 年至 2022 年期间在本医院确诊的所有乳腺淋巴瘤患者进行了回顾性研究。患者数据来自医院记录系统。我们对这些患者进行了随访，以确定每位患者的治疗结果：有 11 名患者被纳入我们的研究范围。所有患者均为女性。平均确诊年龄为（66.1 ± 13）岁。八名患者被诊断为DLBCL，两名患者被诊断为滤泡性淋巴瘤，最后一名患者为淋巴浆细胞性淋巴瘤。化疗+∕-放疗是所有患者的标准治疗方案。四名患者在化疗后一年内去世，五名患者获得完全缓解，一名患者两次复发，目前仍在治疗中，最后一名患者最近才确诊，仍在等待治疗：结论：原发性乳腺淋巴瘤是一种侵袭性疾病。结论：原发性乳腺淋巴瘤是一种侵袭性疾病。手术的作用目前仅限于疾病的诊断。早期诊断和适当治疗对此类病例的治疗至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.